TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03866408

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate weight loss
Description: Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate weight loss
Description: Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Deferred weight loss
Description: Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deferred weight loss
Description: Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
Study: NCT01217931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once daily. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once daily. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once daily. A cycle consists of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once daily. A cycle consists of 4 weeks.
Study: NCT02075333

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rinising of solution
Description: Participants rinse the solution in the oral cavity
Study: NCT04385485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active mobilisation
Description: We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Passive mobilisation with place and hold
Description: We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
Study: NCT04318808

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture
Description: Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
Study: NCT01907152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein enriched yoghurt drink and bread
Study: NCT03864133

Intervention type: DRUG
Group type: OTHER
Intervention: Omidria
Description: Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
Study: NCT02171988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol+pyridostigmine
Description: Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol+pyridostgmine
Description: Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
Study: NCT03658811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intense pulsed light
Description: Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
Study: NCT04235660

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Yttrium-90 Radiation Segmentectomy
Description: This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.
Study: NCT00742742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy life style education
Description: healthy life style education
Study: NCT04235660

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.
Study: NCT03555695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Karate Classes
Description: Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Intervention Focus Group
Description: At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
Study: NCT00742742

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: healthy life style education
Description: healthy life style education
Study: NCT03845166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: oral doses of XL092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: oral doses of XL092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: oral doses of XL092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: oral doses of XL092
Study: NCT03555695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-Intervention Focus Group
Description: At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
Study: NCT03845166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: oral doses of XL092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
Study: NCT01937468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treg-enriched infusion
Description: Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
Study: NCT04547712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive DBS
Description: Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive DBS
Description: Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
Study: NCT01963052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS15E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS15E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS15E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS15E
Description: intravenous (IV) infusion
Study: NCT04594694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Description: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate 200 MG
Description: 200 mg IR tablet of Bezafibrate once daily for the remainder of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 MG
Description: 200 mg IR tablet of Bezafibrate once daily for the remainder of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCA Placebo
Description: One tablet daily for the remainder of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCA Placebo
Description: One tablet daily for the remainder of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate 200 mg Placebo
Description: One tablet daily for the remainder of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 mg Placebo
Description: One tablet daily for the remainder of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate 400 MG
Description: 400 mg SR tablet of Bezafibrate once daily for the remainder of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 MG
Description: 400 mg SR tablet of Bezafibrate once daily for the remainder of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate 400 mg Placebo
Description: One tablet daily for the remainder of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg Placebo
Description: One tablet daily for the remainder of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA
Description: OCA one tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Bezafibrate one tablet will be administered.
Study: NCT05326893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral nerve neurodynamic mobilization
Description: The mobilization was carried out with the patient lying on the non-dominant side in a total flexion position, and the therapist performed the hip extension movement with the knee joint kept in flexion till the patient felt soreness or pain. This position was held for three seconds and then released. This tensioning maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Femoral nerve placebo neurodynamic mobilization
Description: The individual was asked to lie on his non-dominant side and keep his head in the midline. In this position, while the pelvis was stabilized, the upper leg, which was in full knee extension, was grasped and the hip was abducted for 3 seconds. This maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
Study: NCT03005782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Study: NCT00434460

Intervention type: BEHAVIORAL
Intervention: Education
Description: Implementation of clinical practice guideline for ventilator associated pneumonia through education.
Study: NCT01588574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT10109
Description: Botulinum toxin type A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX(Registered trade mark)
Description: Botulinum toxin type A
Study: NCT00397228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTROPANE®
Description: ALTROPANE® SPECT imaging
Study: NCT03271008

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vividtrac videolaryngoscope
Description: During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KingVision videolaryngoscope
Description: During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
Study: NCT03882840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITNK cell therapy
Description: Infusion of ITNK/CAR-ITNK cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITNK cell therapy
Description: Infusion of ITNK/CAR-ITNK cells
Study: NCT03048097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose
Description: a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rubidium
Description: used in PET scans

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging
Description: A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
Study: NCT02406872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: IV pumping for anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: IV pumping for anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: IV pumping for anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: IV bolus for anesthesia
Study: NCT01341509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexor Hallucis Longus Tendon transfer
Description: The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfer of the Flexor Hallucis Longus Tendon
Description: The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No transfer of Flexor Hallucis Longus tendon
Description: There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
Study: NCT00203645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help treatment
Description: Workbook Becoming a Winner,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help treatment
Description: Workbook Becoming a Winner,

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help treatment
Description: Workbook Becoming a Winner,
Study: NCT02124720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSTIM
Description: Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
Study: NCT02613572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00824694

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Self-Monitoring Of Blood Glucose (SMBG)
Description: SMBG will alternate between 2 strategies: glucose profiling and target monitoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Self-Monitoring Of Blood Glucose (SMBG)
Description: SMBG will alternate between 2 strategies: glucose profiling and target monitoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider Training
Description: Focused on normalizing the most significant glucose abnormalities at any given time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider Training
Description: Focused on normalizing the most significant glucose abnormalities at any given time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Focused on normalizing the most significant glucose abnormalities at any given time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Focused on normalizing the most significant glucose abnormalities at any given time.